<?xml version="1.0" encoding="UTF-8"?>
<p id="Par108">In COVID-19 patients who have evidence of EAS activation, treatment with already existing drugs such as the benzodiazepine alprazolam [
 <xref ref-type="bibr" rid="CR15">15</xref>, 
 <xref ref-type="bibr" rid="CR86">86</xref>], the CRH-1 receptor antagonist antalarmin [
 <xref ref-type="bibr" rid="CR6">6</xref>], the alpha-2 adrenoceptor agonist dexmedetomidine [
 <xref ref-type="bibr" rid="CR109">109</xref>, 
 <xref ref-type="bibr" rid="CR187">187</xref>], a beta-1 adrenoceptor blocker, an IL-6 inhibitor (tocilizumab), or even DOPA or DA might prevent positive feedback loops and improve survival. Some of these are undergoing clinical trials now.
</p>
